- Home
- PRAX vs NAGE Comparison
PRAX vs NAGE Comparison
Compare PRAX & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- NAGE
- Stock Information
- Founded
- PRAX 2015
- NAGE 1999
- Country
- PRAX United States
- NAGE United States
- Employees
- PRAX N/A
- NAGE N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- NAGE Medicinal Chemicals and Botanical Products
- Sector
- PRAX Health Care
- NAGE Health Care
- Exchange
- PRAX Nasdaq
- NAGE Nasdaq
- Market Cap
- PRAX 599.7M
- NAGE 594.0M
- IPO Year
- PRAX 2020
- NAGE N/A
- Fundamental
- Price
- PRAX $33.79
- NAGE $6.76
- Analyst Decision
- PRAX Strong Buy
- NAGE Strong Buy
- Analyst Count
- PRAX 9
- NAGE 1
- Target Price
- PRAX $123.33
- NAGE $11.00
- AVG Volume (30 Days)
- PRAX 570.3K
- NAGE 665.7K
- Earning Date
- PRAX 05-12-2025
- NAGE 05-07-2025
- Dividend Yield
- PRAX N/A
- NAGE N/A
- EPS Growth
- PRAX N/A
- NAGE N/A
- EPS
- PRAX N/A
- NAGE 0.11
- Revenue
- PRAX $8,553,000.00
- NAGE $99,597,000.00
- Revenue This Year
- PRAX N/A
- NAGE $21.53
- Revenue Next Year
- PRAX $789.73
- NAGE $20.87
- P/E Ratio
- PRAX N/A
- NAGE $61.45
- Revenue Growth
- PRAX 249.53
- NAGE 19.18
- 52 Week Low
- PRAX $26.70
- NAGE $2.31
- 52 Week High
- PRAX $91.83
- NAGE $9.18
- Technical
- Relative Strength Index (RSI)
- PRAX 43.73
- NAGE N/A
- Support Level
- PRAX $28.79
- NAGE N/A
- Resistance Level
- PRAX $30.88
- NAGE N/A
- Average True Range (ATR)
- PRAX 3.07
- NAGE 0.00
- MACD
- PRAX 0.88
- NAGE 0.00
- Stochastic Oscillator
- PRAX 56.05
- NAGE 0.00
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.